EKF Diagnostics Holdings plc (LON:EKF - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 25.32 and traded as high as GBX 26.50. EKF Diagnostics shares last traded at GBX 26.30, with a volume of 308,789 shares changing hands.
Wall Street Analyst Weigh In
Separately, Stifel Nicolaus reiterated a "buy" rating and set a GBX 35 price target on shares of EKF Diagnostics in a report on Wednesday, April 22nd. One equities research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of GBX 35.
View Our Latest Analysis on EKF Diagnostics
EKF Diagnostics Stock Performance
The company has a market capitalization of £109.78 million, a PE ratio of 54.26 and a beta of 0.49. The company has a current ratio of 4.16, a quick ratio of 1.77 and a debt-to-equity ratio of 2.01. The firm's 50-day simple moving average is GBX 24.86 and its 200-day simple moving average is GBX 25.32.
EKF Diagnostics (LON:EKF - Get Free Report) last released its quarterly earnings data on Tuesday, March 24th. The company reported GBX 0.47 earnings per share (EPS) for the quarter. EKF Diagnostics had a net margin of 4.12% and a return on equity of 3.01%. On average, research analysts predict that EKF Diagnostics Holdings plc will post 2.2987842 earnings per share for the current year.
EKF Diagnostics Company Profile
(
Get Free Report)
EKF is an AIM-listed global diagnostics business focussed on:
● Point-of-Care analysers in the key areas of Hematology and Diabetes
● Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications.
EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider EKF Diagnostics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and EKF Diagnostics wasn't on the list.
While EKF Diagnostics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
